Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre

Epileptic Disorders

Volumn 14, Issue 4, 2012, Pages 379-387

  Steinhoff, Bernhard J ^a   Staack, Anke Maren ^a   Wisniewski, Ilona ^a  

^a Epilepsy Centre Kork   (Germany)

Author keywords

Adult; Antiepileptic drug; Drug combination; Epilepsy; Monotherapy; Seizure control

Indexed keywords

ANTICONVULSIVE AGENT; BROMINE DERIVATIVE; CARBAMAZEPINE; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RETIGABINE; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE CONTROL; FEMALE; HEALTH CARE FACILITY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT; PATIENT REFERRAL; PRIORITY JOURNAL; SEIZURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTICONVULSANTS; CARBAMAZEPINE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 84874603225     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2012.0544     Document Type: Article

References (37)

1. Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003;57:1-13.
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85.
3. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010;51:7-26.
4. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. Epilepsia 2012;53:512-20.
5. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary on the Tenth Eilat Conference (Eilat X). Epilepsy Res 2010;92:89-124.
6. Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002;43:535-8.
7. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
8. Brodie MJ, Overstall PW, Giorgi L. Multicentre, doubleblind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7.
9. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, & Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-8.
10. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007;62:382-9.
11. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998;51:1282-8.
12. Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
13. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6.
14. Deckers CL, Hekster YA, Keyser A, Van Lier HJ, Meinardi H, Renier WO. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001;42:1387-94.
15. Diener HC, Putzki N, Berlit P, et al. Leitlinien für Diagnostik und Therapie in der Neurologie. 4th ed. Stuttgart; New York: Georg Thieme, 2008.
16. Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 2005;65:593-5.
17. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50:63-8.
18. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002;58:S9-20.
19. Guerreiro MM, Vigonius U, Pohlmann H, et al. Adouble-blind controlled, clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-13.
20. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000a; 9:464-8.
21. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000b; 342:314-9.
22. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77.
23. Larkin JG, McLellan A, Munday A, Sutherland M, Butler E, Brodie MJ. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. Br J Clin Pharmacol 1989;27:313-22.
24. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62:375-81.
25. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
26. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285-90.
27. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
28. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy. Epilepsia 1981;22:1-10.
29. Sake J-K, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1055-68.
30. Sheth RD, Harden CL. Screening for bone health in epilepsy. Epilepsia 2007;48:39-41.
31. Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. Br Med J 1977;1:1635-7.
32. Staack AM, Jürges U, Kurth C, Winkler C, Steinhoff BJ. Differential impact of monotherapies with carbamazepine, oxcarbazepine and lamotrigine on clinically relevant laboratory values. Z Epileptol 2007;20:135-42.
33. Steiner TJ, Dellaportas CL, Findley LJ, et al. Lamotrigine monotherpay in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
34. Steinhoff BJ, Ueberall MA, Siemes H, et al. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Seizure 2005;14:597-605.
35. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res 2012;98:194-8.
36. Szaflarski JP, Rackley AY, Lindsell CJ, Szaflarski M, Yates SL. Seizure control in patients with epilepsy: the physician vs. medication factors. BMC Health Serv Res 2008;18:264.
37. Villanueva V, López-Gomáriz E, López-Trigo J, et al. Rational polytherapy with lacosamide in clinical practice: results of Spanish cohort analysis RELACOVA. Epilepsy Behav 2012;23:298-304.